title: [Other antiarrhythmic agents].
abstract: Digitalis decreases the ventricular rates of chronic atrial fibrillation (AF), and is useful in the treatment of patients with AF. Furthermore it is used for atrial flutter and paroxysmal supraventricular tachycardia (PSVT). ATP has been used as a drug of first choice for quick termination of PSVT. In V-HeFT II, the lower mortality in the enalapril arm was attributable to reduction in the incidence of sudden death, probably due to ventricular arrhythmias. Besides, enalapril experimentally increases cardiac refractoriness. In this paper, recent advances in these three drugs are described.
authors.affiliation: 2nd Department of Internal Medicine, Teikyo University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Sato
mesh_terms: D000255:Adenosine Triphosphate / Q000008:administration & dosage; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D000075202:Contraindications; D004071:Digitalis Glycosides / Q000008:administration & dosage; D006801:Humans; D016032:Randomized Controlled Trials as Topic
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D004071:Digitalis Glycosides; D000255:Adenosine Triphosphate